A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

NCT05578092 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

64

Enrollment

INDUSTRY

Sponsor class

Stopped business objectives have changed

Conditions

Solid Tumor
Advanced Solid Tumor
Non Small Cell Lung Cancer
Colo-rectal Cancer

Interventions

DRUG: MRTX0902
DRUG: MRTX849

Sponsor

Mirati Therapeutics Inc.